01 Jan TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

Authored by: Reynes Jacques, Arastéh Keikawus, Clotet Bonaventura, Cohen Calvin, Cooper David A., Delfraissy Jean-François, Eron Joseph J., Henry Keith, Katlama Christine, Kuritzkes Daniel R., Lalezari Jacob P., Lange Joep, Lazzarin Adriano, Montaner Julio S. G., Nelson Mark, O’ Hearn Mary, Stellbrink Hans-Jürgen, Trottier Benoit, Walmsley Sharon L., Buss Neil E., DeMasi Ralph, Chung Jain, Donatacci Lucille, Guimaraes Denise, Rowell Lucy, Valentine Adeline, Wilkinson Martin, Salgo Miklos P.
In: AIDS PATIENT CARE AND STDS 21(8), 2007, p.533-543
http://www.ncbi.nlm.nih.gov/pubmed/17711378